Stough Dow
The Dermatology Clinic, Hot Springs, AR 71913, USA.
J Cosmet Dermatol. 2007 Mar;6(1):9-13. doi: 10.1111/j.1473-2165.2007.00297.x.
This study compared the efficacy of dutasteride vs. placebo in the treatment of male pattern hair loss (androgenetic alopecia) in 17 pairs of identical twin males with androgenetic alopecia over a 1-year period.
In this randomized, double-blind, placebo-controlled, single-center study, one twin from each identical twin pair received dutasteride 0.5 mg/day for 12 months while the other received placebo for 12 months. Hair growth was evaluated using standardized clinical photographs, hair counts, and patient self-assessment questionnaires.
Dutasteride significantly improved hair growth at 1-year compared to placebo based on the analysis of the investigator assessment and the patient self-assessment questionnaires. Sixteen of 17 sets of twins completed the study, of which 15 sets correctly predicted the use of dutasteride. Only one set could not determine the active drug from the placebo.
Through the use of identical twins, this randomized trial provides evidence that dutasteride significantly reduces hair loss progression in men with male pattern hair loss.
本研究比较了度他雄胺与安慰剂在17对患有雄激素性脱发的同卵双胞胎男性中治疗男性型脱发（雄激素性脱发）的疗效，为期1年。
在这项随机、双盲、安慰剂对照的单中心研究中，每对同卵双胞胎中的一人每天服用0.5毫克度他雄胺，持续12个月，而另一人服用安慰剂，持续12个月。使用标准化临床照片、毛发计数和患者自我评估问卷来评估头发生长情况。
根据研究者评估和患者自我评估问卷分析，与安慰剂相比，度他雄胺在1年时显著改善了头发生长。17对双胞胎中有16对完成了研究，其中15对正确预测了使用度他雄胺的情况。只有一对无法区分活性药物和安慰剂。
通过使用同卵双胞胎，这项随机试验提供了证据，证明度他雄胺可显著减少男性型脱发男性的脱发进展。
